CHF Solutions Announces Launch of Ultrafiltration Therapy Using Aquadex FlexFlow® System at Memphis Methodist Le Bonheur Hea...
December 03 2019 - 8:00AM
CHF Solutions (Nasdaq: CHFS) today announced that Memphis,
Tennessee-based health system, Methodist Le Bonheur, has initiated
offering aquapheresis therapy to patients suffering from fluid
overload using the company’s Aquadex FlexFlow system. The use of
the therapy was featured in the Daily Memphian
newspaper https://dailymemphian.com/article/8899/methodist-using-aquapheresis-to-drain-fluid-in
on November 16, 2019.
“As a company, we are dedicated to changing the lives of
patients suffering from fluid overload through science,
collaboration, and innovation,” said John Erb, CEO of CHF
Solutions. “We are proud and honored to be working with
Methodist Healthcare system and look forward to partnering with
their clinicians in the care of their fluid overloaded patients.”
“We are pleased to offer Aquadex FlexFlow therapy to our
patients suffering from fluid overload,” said John Jefferies, MD,
Co-Director, Methodist Cardiovascular Service Line and Jay Michael
Sullivan Distinguished Chair in Cardiology at the University of
Tennessee Health Science Center. “We feel this simplified form of
ultrafiltration may improve the quality of life of our fluid
overloaded patients and could lead to fewer rehospitalizations and
reduce overall costs.”
Methodist Le Bonheur Healthcare (MLH) is an integrated, not-for-
profit healthcare system based in Memphis, Tennessee, with
locations and partners across the Mid-South. Throughout its
history, MLH has remained affiliated with the United Methodist
Church. Faith inspires the hospital to serve its patients and
improve the health of its entire community.
“We continue to invest in our field therapy support organization
to ensure the Aquadex FlexFlow system is providing optimal therapy
to patients suffering from excess fluid,” said Nestor Jaramillo,
CCO of CHF Solutions. “We are excited about this partnership
with Methodist Le Bonheur and the potential to significantly
improve clinical and economic outcomes with the Aquadex FlexFlow
system technology.”
About CHF SolutionsCHF Solutions, Inc. (Nasdaq:
CHFS) is a medical device company dedicated to changing the lives
of patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing, and commercializing the Aquadex FlexFlow
system for ultrafiltration therapy. CHF Solutions is a Delaware
corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
About Aquadex FlexFlow® System The Aquadex
FlexFlow system is a clinically proven therapy that provides a
safe, effective, and predictable method of removing excess fluid
from patients suffering from fluid overload. The Aquadex FlexFlow
system is indicated for temporary (up to eight hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy, and for extended (longer than 8 hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and require hospitalization. The company
has submitted an application to the FDA requesting for 510(k)
clearance of the Aquadex FlexFlow system to include pediatric
patients who weigh 20kg or more. All treatments must be
administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies.
Forward-Looking StatementsCertain statements in
this release are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including
without limitation, statements regarding improvements to clinical
and economic outcomes through use of the Aquadex FlexFlow
system. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risk associated with our ability to execute on our
commercialization strategy, the possibility that we may be unable
to raise sufficient funds necessary for our anticipated operations,
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as
of the date when made. CHF Solutions does not assume any
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com-or- Bret Shapiro Managing Partner CORE IR
516-222-2560 brets@coreir.com www.coreir.com
MEDIA Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024